כסף מזומן למניה Tenax Therapeutics Inc (TENX)

Tenax Therapeutics (TENX) focuses on heart failure and pulmonary hypertension therapies for cardiac centers. The company is currently spending its available capital on costly clinical trials in the absence of profit. This chart on GURU.Markets contains data on cash per share, where the 2.50 indicator expresses the state of the metric. However, a narrow asset profile creates the risk of a price collapse in the event of failed trials.
פילוחי מדדים מקיפים ואנליטיקה עבור Tenax Therapeutics Inc. (TENX)

Orphan drug status provides Tenax Therapeutics (TENX) with a monopoly position and protection against generics. To assess the sustainability of this model, GURU.Markets utilizes cash per share, calculated by dividing liquid assets by the number of shares. This chart visualizes the burn rate of development capital amid expensive borrowing costs. A decline in this metric signals the depletion of the financial cushion, while a stable cash level confirms the company's ability to sustain R&D without emergency equity issuance.